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Summary We have evaluated the value of specific bone resorption markers in monitoring metastatic bone
disease to define the duration of action of a single high-dose pamidronate infusion. Twenty patients received a
single infusion of pamidronate 120 mg for painful bone metastases. Ten out of these 20 patients also received a
second infusion. They were evaluated at baseline, 2, 4 and 8 weeks after each infusion. A composite pain
questionnaire, serum and urine tests were carried out at these time points. Bone resorption markers measured
included urinary calcium, hydroxyproline and two new markers: pyridinoline and deoxypyridinoline. Reference
values were defined by 20 healthy controls matched by age and sex. Pamidronate induced a profound fall in
bone resorption with a maximal effect within the first month after therapy. Changes in urinary calcium levels
were confounded by a rise of 100% in the parathyroid hormone levels. Before treatment, pyridinoline and
deoxypyridinoline were increased in 70% of patients, while urinary calcium was increased in only 40% of them.
Thirteen patients had a > 50% fall in deoxypyridinoline levels and were considered as biochemical responders.
These patients had a mean reduction in pain score of about 30% of baseline levels, which was significantly
higher than the seven non-biochemical responders. In conclusion, urinary calcium is not a precise marker of
bone resorption. Deoxypyridinoline seems to be the most specific bone resorption marker in cancer patients.
Biochemical responders have the most benefit from pamidronate in terms of pain relief. This suggests that
patients may benefit from more potent or repeated infusions of bisphosphonates.
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Bone is the most common site for metastases from breast and
prostate cancer, affecting about 70% of patients with
metastatic disease. These metastases cause considerable
morbidity including bone pain, hypercalcaemia, pathological
fractures, nerve root/spinal cord compression and conse-
quently a decrease in mobility and quality of life. Palliation
of symptoms and improvement in quality of life are the
major therapeutic goals in metastatic bone disease.
Our understanding of the pathophysiology of bone
metastases has increased in the last few years. The most
important mechanism of bone destruction is the release of
paracrine factors (cytokines, growth factors, prostaglandins),
which stimulate osteoclasts to resorb bone (Boyce, 1991).
There is some recent evidence that bone is itself an important
source of growth factors, which following release during bone
resorption, may stimulate tumour growth (Garret, 1993),
creating a stimulatory vicious circle in the bone microenvir-
onment.
Bisphosphonates are agents that inhibit osteoclastic bone
resorption in several ways and might be able to disrupt this
cycle. They may have a direct cytotoxic effect on osteoclasts,
inhibit the migration and transformation of osteoclast
precursors into mature osteoclasts and impede the attach-
ment of osteoclasts to the bone surface (Flanagan and
Chambers, 1989; Lowik et al., 1988).
Bisphosphonates are increasingly being prescribed for
patients with bone metastases. They are the treatment of
choice in hypercalcaemia of malignancy and may be used in
the management of bone pain from bone metastases. They
are also able to prevent skeletal complications such as pain
requiring radiotherapy, reduce the incidence of hypercalcae-
mia and pathological fractures (Van Holten-Verzantvoort et
al., 1993; Paterson et al., 1993; Lahtinen et al., 1992) and,
when associated with chemotherapy, increase the median time
to disease progression in bone (Conte et al., 1994).
There is uncertainty about the ideal schedule of
pamidronate in metastatic bone disease because of the
difficulty in monitoring its effects. Measurement of bone
turnover by biochemical markers is perhaps a more objective
method to evaluate the effects of bisphosphonates on bone.
Urinary calcium (uCa) has traditionally been used to evaluate
bone resorption (Campbell et al., 1983) and is considered the
standard bone resorption marker in oncology, although it
does not exclusively reflect bone resorption. Hydroxyproline
(Hyp) is another traditional bone resorption marker that has
been used to evaluate pharmacological effects on bone
turnover, but has its own sources of inaccuracy (Coleman
et al., 1988).
There is a clear need for more reliable and specific
markers of bone resorption. In the last few years, new
products of collagen breakdown, which are released into the
circulation during bone resorption, have been identified as
bone resorption markers. They are the naturally fluorescent
non-reducible cross-links of collagen: deoxypyridinoline and
pyridinoline (Eyre et al., 1984). Their function is to stabilise
the collagen fibrils by forming bridge linkages (cross-links)
with neighbouring collagen molecules (Eastell, 1994).
Pyridinoline is also found in cartilage, ligament, tendons,
vessels and can be released from the tumour stroma whereas
deoxypyridinoline is found in significant amounts only in
bone and therefore is highly bone-specific (Eyre, 1992).
Cross-links are not influenced by diet (Colwell et al., 1993),
probably not metabolised, and excreted in the urine. They
have primarily been tested in Paget's disease of bone and
osteoporosis. Oncology is a new area of application for
these markers. We have previously reported preliminary
results on the use of urinary excretion of pyridinium cross-
links for monitoring metastatic bone disease (Coleman et al.,
1992).
Pamidronate is the most potent bisphosphonate in clinical
use. Our group has previously reported the clinical results of
this trial of high-dose pamidronate elsewhere (Purohit et al.,
1994). The aims of this study were to confirm the value of
specific resorption markers in monitoring metastatic bone
disease and define the duration of action of a single
pamidronate infusion.
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Patients and methods
Patients
We were able to perform detailed biochemical analysis in 20
of 34 patients that were recruited to this clinical trial. These
patients were only chosen because they had a complete set of
samples collected over 8 weeks after the infusion. The
percentage of patients with pain relief in this subgroup was
similar to the percentage of the whole group. Five were
perimenopausal and 12 post-menopausal women (mean age
48 years, range 32-64; mean years post-menopausal 3, range
0-10) and 3 were men (mean age 63 years, range 51-75).
Fifteen patients had breast cancer, three prostate cancer and
two others. Because of other ongoing trials involving patients
with lytic bone metastases most patients had predominantly
sclerotic bone metastases.
Entry criteria included patients with painful radiologically
confirmed bone metastases, at least one previous chemo- or
hormonal therapy, no bisphosphonate treatment in the
previous 3 months, no other drugs affecting bone metabo-
lism and no concomitant systemic treatment. Analgesics were
allowed. All patients were normocalcaemic at entry to the
study.
The control group consisted of 20 healthy volunteers, 17
women (mean age 51 years, range 47-59; mean years post-
menopausal 4, range 0-10) matched for years post-
menopausal and three men (mean age 59, range 48-71)
matched for age. Fasting serum samples and a second voided
urine sample were collected from them.
All patients received an infusion of pamidronate 120 mg
and were followed up over 8 weeks. Ten patients
subsequently received a second infusion with the same dose
for recurrence of bone pain. This second infusion was given
with a median of 6 weeks (range 2 -10) after the 8 weeks
follow-up of the first treatment. Pamidronate was given over
12 hours in 11 normal saline and subjects were followed up in
the out-patient department.
Biochemical analysis
A fasting morning serum sample and a second voided urine
sample were collected at baseline, 2, 4 and 8 weeks after both
treatments and stored at -20°C. The urine was acidified with
3% hydrochloric acid before storage. All samples from an
individual were analysed in duplicate and in the same batch
to minimise interassay variation.
Routine serum measurements included full blood count
(FBC), serum calcium (sCa) corrected for albumin,
phosphate (P04), creatinine, urea, parathyroid hormone
(PTH) and total alkaline phosphatase. Two bone formation
markers were also measured: osteocalcin (Oc) and bone
alkaline phosphatase (bAP).
Intact PTH was measured by a two-site immunoradio-
metric assay (Allegro PTH, Nichols Institute, San Juan
Capistrano, CA, USA). The detection limit of the assay is
1 pg ml-'. The intra-assay and interassay variability were 5%
and 5.5% respectively. Osteocalcin was measured by a two-site
immunoradiometric assay that measures intact osteocalcin
(1-49 peptides) and the large N-terminal mid-fragment (1-43
peptides) using human osteocalcin as standard (Elsa-Osteo,
CIS, Gif-sur-Yvette, France). Samples may be stored at
-20°C for this osteocalcin assay as it is less sensitive to
storage conditions than other commercial assays (Blumsohn,
1995a). This assay is claimed to have less in vitro proteolytic
degradation when exposed to room temperature than other
assays used to measure osteocalcin (Garnero et al., 1994a).
The detection limit of the assay is 0.4 ng ml- '. The intra-assay
and interassay variability were 5.8% and 7% respectively.
Bone alkaline phosphatase was measured by a precipitation
method that makes use of the affinity of the wheatgerm lectin
for the bone isoenzyme (Rosalki and Foo, 1984). The amount
of the bone isoenzyme is calculated by subtracting the total
alkaline phosphatase from the supernatant (liver isoenzyme).
Roche uni-kit III was used for analysis with the application of
a COBAS machine. The intra-assay and interassay variability
were 5.8% and 7% respectively.
Urinary creatinine was measured using an automated
chemistry analyser using a kinetic Jaffe method and all the
urinary markers are expressed as a ratio to creatinine
excretion. Urinary calcium was measured by a colorimetric
assay. Hydroxyproline was measured by a colorimetric assay
with dimethylaminobenzaldehyde after acid hydrolysis and
chloramine T oxidation.
Total pyridinoline (Pyd) and deoxypyridinoline (Dpd) were
measured in duplicate after acid hydrolysis, CFI cellulose
column partition chromatography, and reverse-phase high-
performance liquid chromatography (HPLC) with fluores-
cence detection (Colwell et al., 1993). The intra-assay and
interassay variability were 8.5% and 12.5% respectively.
Response criteria
At each visit the scores for pain intensity, WHO performance
status and analgesic consumption were combined to produce
an overall pain score (Coleman, 1994). Subjective response to
treatment was defined as >20% decrease in the pain score
compared with the baseline on at least two consecutive
measurements. Patients with pain decrease <20% were
considered non-subjective responders (Purohit et al., 1994).
Biochemical response to treatment was defined as > 50%
decrease in the deoxypyridinoline (which is the most bone-
specific resorption marker) value compared with the baseline
value. Patients with <50% decrease in the deoxypyridinoline
values were considered as non-biochemical responders. This
value was chosen because this is the usual cut-off point
between response or not to treatment in cancer patients.
Statistical methods
Most markers showed a skewed distribution, so the data were
logarithmically and back transformed, expressed as
mean+standard error and shown as the percentage (%) of
baseline values of each infusion, except for serum calcium
and phosphate which are expressed as mmol 1-'. For
comparison of baseline measurements of patients and
controls, the unpaired t-test was used. The reference range
was defined non-parametrically as between the 2.5% and
97.5% percentiles. A paired t-test with Bonferroni correction
was used to compare changes in markers over time. As three
comparisons were made, P<0.017 was considered significant.
Baseline values of both infusions were compared by the
paired t-test with P<0.05 considered as significant. The area
under the response curve (AUC) of each marker in both
infusions was determined and compared with an AUC
assuming no change over the 8 weeks with P< 0.05
considered as significant.
Comparisons between biochemical responders and non-
responders and between first and second infusions were done
by multifactor analysis of variance using the Scheffe test.
Pearson correlation coefficients between markers at baseline
and between AUC after treatment were determined. Pearson
correlation was also used to compare percentage of pain score
change and percentage decrease in deoxypyridinoline levels.
Results
General biochemistry and haematology
Serum calcium showed a significant decrease after the first
infusion at 2 and 4 weeks (Table I). The AUC for calcium
after the first infusion also showed a significant decrease
(P<0.003). Serum calcium also fell after the second infusion,
but this was not significant. The AUC of serum phosphate
fell significantly after both infusions (P< 0.02 after the first
infusion and P<0.01 after the second infusion). PTH levels
increased at 2 and 4 weeks after the first infusion by > 100%,
(Table I), with every patient showing at least a 20% increase
compared with baseline values. The AUC also showed a
significant increase (P<0.005). Following the second infu-
sion, PTH increased by 65% at 2 weeks (P<0.01) and by
23% at 4 weeks (NS) (Table I).
Bone formation
Baseline values of bone and total alkaline phosphatase were
increased significantly, contrasting with osteocalcin results
(Table II). Osteocalcin and bone alkaline phosphatase
decreased by 15% at 8 weeks after both infusions, but this
was not statistically significant (Figure 1). Bone alkaline
phosphatase decreased by 30% at 8 weeks after the second
infusion compared with the baseline of the first infusion, but
this also did not reach statistical significance. There was no
correlation between osteocalcin and bone alkaline phospha-
tase at baseline (r = 0.3) or AUC of the first infusion (r = 0.2).
Bone resorption
All resorption markers, except urinary calcium, were
increased significantly at the beginning of treatment, with
pyridinoline and deoxypyridinoline being the most frequently
increased markers (70%). The spread of pretreatment values
is shown in Figure 2. Before the second infusion, only
pyridinoline and deoxypyridinoline were significantly in-
creased when compared with controls (t-test). Urinary
calcium was increased in only 40% and 20% of patients
before the first and second infusions respectively (Table II).
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Urinary calcium, hydroxyproline, pyridinoline and deoxy-
pyridinoline fell significantly at all time points after the first
infusion (Figure 3). The AUC approach also showed that
there was a significant decrease in these markers (P<0.001).
After the second infusion, the resorption markers fell
significantly at 2 and 4 weeks compared with baseline of
this infusion except for hydroxyproline, owing to high
interpatient variability. The shape of the curve response of
this infusion was similar to the first infusion.
Before the first treatment, 70% patients had increased
Dpd values. Within a month, 50% of these patients had
normalised Dpd values. However, after 8 weeks only 15% of
these patients still had normal values. Before the second
infusion, 70% patients had increased Dpd values. Within a
month, >50% of patients had normalised Dpd values.
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Figure 1 Bone formation markers after the first infusion. Values
expressed as percentage of the mean+ s.e.m. (no significant
changes). bAP, (- - -); Oc (- ).
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Figure 2 Baseline values of resorption markers. The upper limit
of normal for each marker is indicated by a line.
Table I Serum calcium, phosphate and PTH levels expressed as mean+ s.e.m.
First infusion Second infusion
Baseline 2 weeks 4 weeks 8 weeks Baseline 2 weeks 4 weeks 8 weeks
Ca 2.4 +.03 2.2 ±.03* 2.3 ±.03* 2.3 +.03 2.3 ±.05 2.2±.05 2.3 ±.05 2.3 ±.05
P04 1.2±.04 1.0 ±.04* 1.1 +.05 1.1 ±.05 1.23 +.07 1.09+.07 1.08 +.07* 1.1 ±.06
PTH 100 220 ± 29* 215±31* 127±21 100 162 + 19* 123 + 11 118 ± 18
Ca and P04 expressed as mmol 1-1. PTH expressed as percentage of baseline levels. Paired t-test with Bonferroni correction. *P<0.017.
Table II Baseline markers of bone turnover measured in controls and patients at first and second infusions
Oc Bap Hyp Uca Dpd Pyd
ngml' ur] jimolmmor' mmolmmor' nmolmmol1 nmolmmol'
Control mean 22 35 22 0.27 6.1 24
2.5 -97.5 percentiles 12-36.6 25-65.3 12.7-41.6 0.09-0.42 3.4-11.8 15.2-41.7
Patients mean+ s.e.m. - 25 + 5 67±15** 47 ± 6** 0.35 ± 0.06 15 ± 2.5** 62+ 12**
first infusion
Percentage of patients with 40% 65% 55% 40% 70% 70%
high values-first infusion
Patients mean + s.e.m. - 32 ± 15 65 + 18* 32 ± 9 0.24 ± 0.06 14 ± 5* 63 ± 16**
second infusion
Percentage of patients with 40% 50% 50% 20% 70% 70%
high values -second
infusion
Urinary markers are expressed as a ratio to creatinine. *P<0.05, **P<0.01, in comparison with controls.
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However, after 8 weeks only 20% of patients still had normal
values. Before the first treatment, 40% had increased uCa
levels. Within a month, 90% of patients had normal levels,
which persisted for >8 weeks. Before the first infusion, 70%
and 55% of patients had increased Pyd and Hyp values
respectively. Among them, 30% and 50% of patients
normalised these values respectively.
The Pyd/Dpd ratio was significantly higher in patients at
baseline compared with controls (4.4 vs 3.9 respectively). This
ratio increased significantly at 2 weeks to 6.5 and then
decreased to 5.7 at 4 weeks and 5.1 at 8 weeks. The effects of
each treatment on bone turnover markers over the 8 weeks
were compared by multifactor analysis of variance. No
significant differences in biochemical effects between the two
infusions was identified (P= 0.22). Urinary calcium was
excluded from this analysis because its levels were influenced
by PTH.
Pain relief and biochemical response
Two patients received dexamethasone and radiotherapy,
which make the interpretation of the change in the pain
score difficult, were considered non-assessable. The mean
pain score in the remainder fell at 2 weeks and remained
practically unchanged to 8 weeks (Figure 4), reflecting the
decrease in bone resorption. Before the second infusion, the
pain score increased again but fell with retreatment (Figure
4).
Thirteen patients showed a subjective response. Of these,
11 were also biochemical responders. The other two patients
only had a 30% reduction in Dpd. Five patients were non-
subjective responders and of these, only two were considered
biochemical responders.
In total, there were 13 biochemical responders and seven
non-responders. All of the non-responders also showed
<50% reduction in pyridinoline and four had <50%
reduction in hydroxyproline values, whereas all of them
showed > 50% reduction in urinary calcium levels.
Biochemical responders showed a greater relief of pain
when compared with non-responders by multifactor analysis
of variance (P<0.01) (Figure 5). There was a significant
correlation between the maximum decrease in pain score (%)
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and the maximum decrease (%) in deoxypyridinoline levels
(r=0.51, P<0.05). However, changes in pain score did not
correlate with changes in any of the other resorption markers.
Seven out of ten patients responded subjectively to
treatment after the second infusion. Among these, six were
biochemical responders. Three patients did not show pain
relief. Among those, two were considered non-biochemical
responders.
In the ten patients who received both infusions, baseline
levels of bone markers at both infusions were compared.
Although there was some carry-over effect from the first
infusion (Figure 4), none of the markers showed a
statistically significant difference. Pearson correlation coeffi-
cients of the baseline and AUC values after the first infusion
are shown in Table III. There was a significant correlation
between Dpd, Pyd and Hyp before and during treatment
(AUC values). However there was no correlation at any time
with urinary calcium. After the second infusion, correlations
between Dpd, Pyd and Hyp were significant at baseline: Dpd
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Figure 4 Pain score and bone resorption markers of the ten
patients that received two infusions. Resorption markers
expressed as percentage of the mean of pretreatment
values. ---, Pain;- - -, Pyd;- - - - -, Hyp;
Dpd; ---, uCa.
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Figure 3 Bone resorption markers after the first infusion. Values
expressed as percentage of the mean+s.e.m. (P<0.017 at all time
points). -O-, Pyd; - - -O- - -, Hyp; -A-, Dpd; --, uCa.
Figure 5 Pain score comparison of objective and non-objective
responders after first infusion. Significance level by multifactor
analysis of variance. (P= <0.01). - - -, Non-biochemical
responders; , biochemical responders.
Table III Pearson correlation coefficients of markers at first infusion
uCa Hyp Pyd Dpd
Baseline AUC Baseline AUC Baseline AUC Baseline AUCG
uCa - - 0.15 0.27 0.17 -0.06 0.19 -0.05
Hyp 0.1 0.3 - - 0.83** 0.5* 0.74** 0.5*
Pyd 0.17 -0.06 0.83** 0.5* - - 0.9** 0.88**
Dpd 0.19 -0.05 0.74** 0.5* 0.9** 0.88** - -
AUC, area under the curve. *P<0.05, **P<0.003.
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vs Pyd: r=0.92, P<0.005; Dpd vs Hyp: r=0.88, P<0.017;
Pyd vs Hyp: r=0.77, P<0.017, but none of them correlated
with uCa. The AUC of Dpd and Pyd correlated significantly
(r=0.72, P<0.05), but again none of them correlated with
urinary calcium.
Discussion
Objective evaluation of the response in bone to therapy is a
challenge. Therefore, there is a clear need for new methods of
response assessment in bone. Changes in biochemical markers
can be determined in the first few weeks after the beginning
of a therapy. There are a number of markers being used in
oncology to monitor cancer therapy, such as CA-125, a-
fetoprotein and human chorionic gonadothrophin.
In this trial, pamidronate induced a profound fall in bone
resorption, with a maximum effect seen at 2 weeks. Indeed,
studies in hypercalcaemia of malignancy (Coleman and
Rubens, 1987; Vinholes et al., 1995) suggest that the
maximal effect on bone resorption occurs even earlier than
2 weeks. After two weeks there was a steady progressive
increase in bone resorption, but significant inhibition
persisted throughout the 8 weeks of observation.
The inhibition of bone resorption reduces the release of
calcium from the skeleton to the circulation, which was
evidenced by the fall in serum calcium after both treatments.
A statistically significant fall in the serum calcium of
normocalcaemic breast or prostate cancer patients has
previously been observed after clodronate (Thiebaud et al.,
1991; Martoni et al., 1991) and pamidronate (Lipton et al.,
1994). As calcium homeostasis is tightly controlled by PTH,
even relatively small falls in calcium levels, induce a negative
feedback in the parathyroid glands within a few minutes. The
accuracy of this process is impressive, allowing serum calcium
to change only about 0.025 mmol 1-1 during the day
(Broadus, 1993). We observed a marked increase in PTH
levels after both infusions, with some effects still persisting at
8 weeks. A significant increase in PTH levels after oral and
intravenous (i.v.) pamidronate was also found by other
investigators (Reid et al., 1994; Body et al., 1995) and also
after i.v. clodronate (Pecherstorfer et al., 1993). PTH acutely
regulates serum calcium by increasing distal renal tubular
reabsorption of calcium, hence decreasing urinary calcium
excretion. Furthermore, PTH leads to a decrease in distal and
proximal renal tubular reabsorption of phosphate, resetting
the renal tubular threshold of phosphate at a lower level.
Urinary calcium has been used to measure bone resorption
for more than three decades. Most published reports about
the effects of bisphosphonates in cancer patients have relied
on urinary calcium to monitor bone resorption (O'Rourke et
al., 1995). Although uCa is a cheap and easy to measure
assay, it can be influenced by diet, renal function, parathyroid
hormone, parathyroid hormone-related protein and seems to
reflect the balance of bone turnover, rather than bone
resorption specifically (Blomqvist et al., 1987). Compared
with the other resorption markers, relatively few patients had
increased baseline values in this trial. This confirms the
findings of a recently published study that compared 143
normal controls with 98 cancer patients with bone metastases
and showed no significant increase in urinary calcium
between cancer patients (mainly breast cancer) with bone
metastases and controls (Pecherstorfer et al., 1995). In
addition in our study, within a month after pamidronate,
< 10% of patients had abnormal urinary calcium values,
while 35% of patients had Dpd levels above the normal
range. Therefore, urinary calcium does not seem to be a
sensitive marker of bone resorption.
Not surprisingly, urinary calcium did not correlate with
any other resorption marker at baseline or by comparison of
areas under the curve after both treatments. This lack of
correlation with other resorption markers has also been noted
in previous studies (Coleman et al., 1992; Body and Delmas,
1992). This is explained by the fact that urinary calcium is
not only monitoring changes in bone turnover, but is also
reflecting the renal handling of calcium by PTH whereas
cross-links reflect the metabolism of the bone collagen (Seibel
et al., 1994). The absence of correlation of changes in urinary
calcium with pain score confirms some recently published
data (O'Rourke et al., 1995).
Hydroxyproline is an imino acid present in significant
amount in all collagenous tissues (including bone), elastin
and complement factor Clq. It is estimated that about 80%
of hydroxyproline is metabolised in the liver by hydroxypro-
line oxidase and only 10% is excreted in the urine (Eastell,
1994). Because serum levels of hydroxyproline can be
influenced by diet or soft tissue destruction by extraskeletal
metastases it does not have the profile of an accurate
resorption marker. The fall in hydroxyproline was not
statistically significant after the second infusion.
Pyridinoline and deoxypyridinoline were increased in 70%
of patients. They have also been shown to be significantly
increased in other reports (Coleman et al., 1992; Lipton et al.,
1993; Pecherstorfer et al., 1995). Ninety per cent of patients
had mainly osteosclerotic disease, in which bone resorption is
not increased as much as it is in lytic or mixed bone
metastases.
Pyridinoline and deoxypyridinoline showed a consistent
mean decrease of 30% and 42% respectively after both
infusions. There was also a significant correlation between
Pyd and Dpd at baseline and with treatment using the AUC
values, with hydroxyproline, but no correlation with urinary
calcium.
The Dpd/Pyd ratio was increased in these patients, which
is supported by recent similar findings (Pecherstorfer et al.,
1995; Behrens et al., 1995). This increase may be explained by
the fact that many patients also had concomitant soft tissue
metastases and it is known that there is a soft tissue
component to the urinary excretion of pyridinoline. These
soft tissue metastases possibly progressed during the trial as
these patients were not receiving any systemic anti-cancer
therapy. The decrease in the ratio towards normal after 2
weeks is probably due to the reactivating bone metastases.
Dpd showed a greater decrease than Pyd after both infusions,
resulting in a significant increase in the Pyd/Dpd ratio after
treatment, probably reflecting the higher bone specificity of
deoxypyridinoline. Similar observations were made in a
previous study on oral pamidronate (Coleman et al., 1992).
This increased Pyd/Dpd ratio in cancer patients suggests that
deoxypyridinoline is a more reliable marker in this situation
than pyridinoline.
The changes in pain score seem to follow the changes in
resorption markers and suggest that these markers could be
used to monitor antiresorptive therapy. At the time of the
second treatment when patients had recurrent bone pain, the
pamidronate effects on bone resorption had faded away and
bone resorption was increasing again. This suggests a positive
relationship between increased bone resorption and bone pain
and the need of further treatment in responsive patients. The
significant, although somewhat weak correlation, between
changes in Dpd and pain score also reinforces this possibility.
The significantly greater decrease in pain score in patients
considered as biochemical responders is interesting and
suggests that more potent bisphosphonates that are capable
of reducing bone resorption further may be clinically superior
to currently available compounds. We have taken 50% as a
cut-off point because this is a widely accepted index of
markers and biochemical response in clinical oncology and
we intend to evaluate this prospectively in a trial in which we
are comparing high-dose pamidronate with placebo for
painful bone metastases.
Bone formation markers remained unchanged over the
first month, beginning to fall at 8 weeks and with some carry-
over effect to the next dose. Close follow-up over a longer
period of time is needed to assess possible clinically
important reductions in the rate of bone formation with
long-term bisphosphonate use. Bone alkaline phosphatase
was elevated in two-thirds of the patients and was a more
Pamiionk-f in metastaUic borne ime
J Vrxodles et al
1094
sensitive indicator of bone formation than osteocalcin. which
was elevated in only 40% of patients at baseline.
Interestingly, there was no significant correlation between
these formation markers, as previously described (Li et al.,
1993), possibly because bone alkaline phosphatase reflects the
synthesis of the organic bone matrix while osteocalcin reflects
the mineralisation process.
The shape of the time curve response of bone metabolism
markers was similar after both infusions. Resorption markers
are the first to decrease and are followed by the formation
markers about 6-8 weeks later. This reflects the coupling
process of bone resorption and formation, in a process
known as bone remodelling. The entire process takes about
3-4 months with bone formation only normally occurring in
areas of bone undergoing resorption (Mundy, 1995).
The optimal choice of bone metabolism markers remains
an area for debate. Bone formation markers only begin to fall
about 8 weeks after therapy, so they obviously cannot reflect
the effects of therapy before this time. Among the resorption
markers, deoxypyridinoline seems to be the best candidate to
monitor therapy. Patients with abnormal Dpd values might
benefit from a second infusion of pamidronate if these values
are still above the normal range and or to perpetuate a
subjective response.
Although deoxypyridinoline is a more specific and reliable
resorption marker, the HPLC technique is notoriously
cumbersome and time consuming, an important obstacle to
routine use in monitoring therapy in cancer patients.
Recently, some immunoassays to measure peptide-bound
cross-links such as the N-telopeptide-NTX- (Hanson et al.,
1992) and the C-telopeptide of type I collagen-Crosslaps-
(Garnero, 1994b) have been developed. They have shown a
good correlation with deoxypyridinoline and pyridioline and
are much easier to measure (Blumsohn et al., 1995b).
In conclusion, we can confirm that pamidronate is a
potent inhibitor of bone resorption in patients with
metastatic bone disease. Comparative tnrals of dose, potency
and schedule are needed to determine the true relationship
between biochemical and clinical effects, but our paper
suggests that repeated doses or more potent bisphosphonates
may be clinically even more effective. As there is a possibility
that a placebo effect could have contnrbuted to the subjective
response, we are now carrying out a randomised double-blind
placebo-controlled study. Urinary calcium is not a sensitive
or specific marker of bone resorption. Deoxypyridinoline
seems to be the best resorption marker to monitor therapy,
although pain is complex and only partially related to the
rate of bone resorption. The availability of specific bone
resorption markers will be helpful for selecting and
monitoring the optimal schedule of bisphosphonates in
cancer patients.
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